The Acid Form of CBD Was Absorbed at Dramatically Higher Levels Than CBD Itself in Mice
Cannabidiolic acid (CBDA) reached blood concentrations roughly 100 times higher than CBD when given at the same dose to mice, suggesting it may be far more bioavailable.
Quick Facts
What This Study Found
CBDA plasma concentrations in mice were approximately two orders of magnitude (100x) higher than CBD under identical dosing conditions. Nanomicelle encapsulation improved bioavailability for both compounds in vitro and in vivo.
Key Numbers
CBDA plasma levels approximately 100x higher than CBD at the same dose; 10 cannabinoids and cannabinoid acids tested; nanomicelle encapsulation improved bioavailability; UHPLC-HRMS/MS analysis used
How They Did This
Researchers tested 10 cannabinoids and cannabinoid acids using an in vitro intestinal cell model (Caco-2) and an in vivo mouse model. They also tested CBD and CBDA encapsulated in nanomicelles. Analysis used ultra-high performance liquid chromatography with mass spectrometry.
Why This Research Matters
CBD products dominate the consumer market, but this study suggests the naturally occurring acid form (CBDA, found in raw cannabis) may be absorbed far more efficiently. This could change how cannabinoid products are formulated and dosed.
The Bigger Picture
Most cannabis processing converts CBDA to CBD through heating (decarboxylation). If CBDA is dramatically more bioavailable, the industry convention of decarboxylating cannabis products may actually reduce their therapeutic potential.
What This Study Doesn't Tell Us
Mouse model may not reflect human absorption, single dose tested, long-term effects of CBDA vs CBD not compared, nanomicelle formulation adds complexity, in vivo results from inbred mouse strain
Questions This Raises
- ?Does CBDA's higher bioavailability translate to greater therapeutic effects in humans?
- ?Would lower CBDA doses achieve the same effects as standard CBD doses?
- ?Why has CBDA received so little research attention compared to CBD?
Trust & Context
- Key Stat:
- CBDA plasma levels were approximately 100x higher than CBD at equivalent doses in mice
- Evidence Grade:
- Preclinical study with both in vitro and in vivo data from one mouse strain; novel finding but needs human confirmation
- Study Age:
- Published 2025
- Original Title:
- Unlocking the resorption potential of cannabidiolic acid: A comprehensive in vitro and in vivo bioavailability study.
- Published In:
- International journal of pharmaceutics, 684, 126110 (2025)
- Authors:
- Binova, Zuzana(2), Kucerova, Emilie, Nejedly, Tomas, Viktorova, Jitka, Cahova, Monika, Benes, Frantisek, Maly, Matej, Maly, Martin, Stupak, Michal, Kastanek, Petr, Hajslova, Jana, Stranska, Milena
- Database ID:
- RTHC-06070
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is CBDA and how is it different from CBD?
CBDA (cannabidiolic acid) is the natural form of CBD found in raw cannabis plants. Heat converts CBDA to CBD. This study found CBDA was absorbed about 100 times more efficiently than CBD in mice.
Could CBDA be more effective than CBD?
Possibly. CBDA reached dramatically higher blood levels than CBD at the same dose in mice. Whether this translates to greater therapeutic effects in humans hasn't been tested yet.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-drinks-vs-edibles-body-processes
- homemade-vs-store-bought-edibles-safety
- how-to-store-edibles-shelf-life-potency
- cannabis-dosing-guide-how-much-thc
- what-is-tincture-different-from-edible
- how-to-avoid-greening-out-dosing-prevention
Cite This Study
https://rethinkthc.com/research/RTHC-06070APA
Binova, Zuzana; Kucerova, Emilie; Nejedly, Tomas; Viktorova, Jitka; Cahova, Monika; Benes, Frantisek; Maly, Matej; Maly, Martin; Stupak, Michal; Kastanek, Petr; Hajslova, Jana; Stranska, Milena. (2025). Unlocking the resorption potential of cannabidiolic acid: A comprehensive in vitro and in vivo bioavailability study.. International journal of pharmaceutics, 684, 126110. https://doi.org/10.1016/j.ijpharm.2025.126110
MLA
Binova, Zuzana, et al. "Unlocking the resorption potential of cannabidiolic acid: A comprehensive in vitro and in vivo bioavailability study.." International journal of pharmaceutics, 2025. https://doi.org/10.1016/j.ijpharm.2025.126110
RethinkTHC
RethinkTHC Research Database. "Unlocking the resorption potential of cannabidiolic acid: A ..." RTHC-06070. Retrieved from https://rethinkthc.com/research/binova-2025-unlocking-the-resorption-potential
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.